메뉴 건너뛰기




Volumn 45, Issue 8, 2006, Pages 1002-1003

Adverse reactions to gefitinib (Iressa®): Revealing sycosis- and pyoderma gangrenosum-like lesions [16]

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; BETAMETHASONE VALERATE; CISPLATIN; CORTICOSTEROID DERIVATIVE; ETHACRIDINE LACTATE; GEFITINIB; KETOCONAZOLE; NAVELBINE;

EID: 33746610596     PISSN: 00119059     EISSN: 13654632     Source Type: Journal    
DOI: 10.1111/j.1365-4632.2006.02749.x     Document Type: Letter
Times cited : (24)

References (8)
  • 1
    • 0025280342 scopus 로고
    • Immunolocalization of epidermal growth factor receptors in normal developing human skin
    • Nanney LB, Stoscheck CM, King LE Jr, et al. Immunolocalization of epidermal growth factor receptors in normal developing human skin. J Invest Dermatol 1990; 94: 742-748.
    • (1990) J Invest Dermatol , vol.94 , pp. 742-748
    • Nanney, L.B.1    Stoscheck, C.M.2    King Jr., L.E.3
  • 2
    • 0036051312 scopus 로고    scopus 로고
    • Follicular and epidermal alterations in patients treated with ZD1839 (Iressa), an inhibitor of the epidermal growth factor receptor
    • Van Doorn R, Kirtschig G, Scheffer E, et al. Follicular and epidermal alterations in patients treated with ZD1839 (Iressa), an inhibitor of the epidermal growth factor receptor. Br J Dermatol 2002; 147: 598-601.
    • (2002) Br J Dermatol , vol.147 , pp. 598-601
    • Van Doorn, R.1    Kirtschig, G.2    Scheffer, E.3
  • 5
    • 0035724536 scopus 로고    scopus 로고
    • Cutaneous side-effects in cancer patients treated with the antiepidermal growth factor receptor antibody C225
    • Busam KJ, Capodieci P, Motzer R, et al. Cutaneous side-effects in cancer patients treated with the antiepidermal growth factor receptor antibody C225. Br J Dermatol 2001; 144: 1169-1176.
    • (2001) Br J Dermatol , vol.144 , pp. 1169-1176
    • Busam, K.J.1    Capodieci, P.2    Motzer, R.3
  • 7
    • 0036139727 scopus 로고    scopus 로고
    • Pharmacodynamic studies of the epidermal growth factor receptor inhibitor ZD1839 in skin from cancer patients: Histopathologic and molecular consequences of receptor inhibition
    • Albanell J, Rojo F, Averbuch S, et al. Pharmacodynamic studies of the epidermal growth factor receptor inhibitor ZD1839 in skin from cancer patients: Histopathologic and molecular consequences of receptor inhibition. J Clin Oncol 2002; 20: 110-124.
    • (2002) J Clin Oncol , vol.20 , pp. 110-124
    • Albanell, J.1    Rojo, F.2    Averbuch, S.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.